Founded in January 2016, SapVax is a preclinical stage biotechnology company developing powerful therapeutic peptide-based cancer vaccines. The company has built a proprietary immuno-oncology platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate tunable, fully-synthetic, self-adjuvanting peptide vaccines. SapVax is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.

management team